article · International Journal of Research in Medical Sciences
Background: Diabetic foot infection is a serious risk of amputation and death. Our study aims to describe the epidemiological, clinical, biological, therapeutic and evolutionary profiles of patients hospitalized for infected diabetic foot. Methods: This is a descriptive cross-sectional study conducted in the Endocrinology department of the Joseph Raseta Befelatanana University Hospital, Antananarivo over a period of 4 years. The diagnosis of infected diabetic foot was made according to the criteria of the French-Speaking Society of Infectious Pathology. We included all patients who had undergone bacteriological examination with antibiogram of their diabetic foot lesion. Results: Fifty patients were retained, giving a hospital prevalence of 2.84%. Their mean age was 55.50±9.63 years, the sex ratio was 0.72 and mean duration of their diabetes was 6.87±6.13 years. The majority of the lesions were post-traumatic (28%). The mean hospital length stay was 42.82±35.26 days. Infections were classified as stage 4 for 72% of the patients. The main isolated bacteria were Staphylococcus aureus (54.69%), of which 83% were sensitive to Amoxicillin-Clavulanic Acid. Seventy percent of the patients were infected with multidrug-resistant bacteria. The amputation rate was 30% and the mortality rate was 2%. Conclusions: Therapeutic education on podiatric care must be optimized. Multi-disciplinarity is essential for management. Amoxicillin-clavulanic acid should be preferred as probabilistic antibiotic therapy for diabetic foot infection in our country where bacteriological examination is often lacking.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.18203/2320-6012.ijrms20251288
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.